



PATENT

Our Docket: P-AR 4951

5/7DS  
RECEIVED  
MAY 15 2002  
TECHNOLOGY CENTER 3700

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of )

Gerald W. DeVries )

Serial No.: 10/081,126 )

Filed: February 22, 2002 )

For: METHODS OF EXTENDING CORNEAL )  
GRAFT SURVIVAL )

Examiner: Not yet assigned

Group Art Unit: 3731

I hereby certify that this correspondence is being deposited with  
the United States Postal Service as first class mail in an envelope  
addressed to: Commissioner for Patents, Washington, D.C.  
20231, on May 7, 2002.

By Andrea L. Gashler  
Andrea L. Gashler, Reg. No. 41,029

Commissioner for Patents  
Washington, D.C. 20231

May 7, 2002  
Date of Signature

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.97, enclosed are references relating to the above-identified application. For the convenience of the Examiner, these references are listed on the attached Form PTO-1449, and a copy of each is enclosed herewith.

It is respectfully requested that these references be considered in the examination of this application and that their consideration be made of written record in the application file.

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-0370.

Respectfully submitted,

Date: May 7, 2002

Andrea L. Gashler  
Andrea L. Gashler  
Registration No.: 41,029  
Telephone: (858) 535-9001  
Facsimile: (858) 535-8949

Campbell & Flores LLP  
4370 La Jolla Village Drive  
7<sup>th</sup> Floor  
San Diego, California 92122  
USPTO CUSTOMER NO. 23601

OFFICE  
2002 8 1 AM

Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTN DOCKET NO: P-AR 4951	SERIAL NO. 10/081,126
	APPLICANT: Gerald W. DeVries	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: February 22, 2002	GROUP: 3731

RECEIVED  
JUL 1 2002  
TECHNICAL CENTER

### U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
		5,443,505	08/22/1995	Wong et al.	623	4	8-22-95
		5,869,079	02/09/1999	Wong et al.	424	426	2-9-99

### FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION (YES/NO)

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

		Callanan et al., "Characteristics of Rejection of Orthotopic Corneal Allografts in the Rat," <u>Transplantation</u> 45:437-443 (1988)
		Clayson, "Corneal Lymphatics and Grafts," <u>The Lancet</u> 10:1291-1292 (1966)
		Cohen et al., "A platelet-activating factor antagonist reduces corneal allograft inflammation and neovascularization," <u>Curr. Eye Res.</u> 13:139-144 (1994)
		Collin, "Lymphatic drainage of <sup>131</sup> I-albumin from the vascularized cornea," <u>Invest. Ophthalmol.</u> 9:146-155 (1970)
		Collin, "Corneal lymphatics in alloxan vascularized rabbit eyes," <u>Invest. Ophthalmol.</u> 5:1-13 (1966)
		Cursiefen et al., "Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor $\alpha$ , and transforming growth factor $\beta_1$ in human corneas with neovascularization," <u>Cornea</u> 19:526-533 (2000)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: 1951	SERIAL NO: 10/084,126
	APPLICANT: Gerald W. De Vries	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: February 22, 2002	GROUP: 3731

	Engh et al., "Crystal structures of catalytic subunit of cAMP-dependent protein kinase in complex with isoquinolinesulfonyl protein kinase inhibitors H7, H8, and H89," <u>J. Biol. Chem.</u> 271:26157-26164 (1996)
	Fine and Stein, "The role of corneal vascularization in human corneal graft reactions," In: <u>Corneal Graft Failure</u> (Ciba Foundation Symposium)pp. 193-204 Scientific Publishers: Amsterdam, Holland (1973)
	Foulks, "Clinical aspects of corneal allograft rejection," In: <u>Cornea: Surgery of the Cornea and Conjunctiva</u> (Krachmer et al., eds.) 138:1687-1696 (1997)
	Fournier et al., "Mutation at tyrosine residue 1337 abrogates ligand-dependent transforming capacity of the FLT4 receptor," <u>Oncogene</u> 11:921-931 (1995)
	Fournier et al., "Role of tyrosine residues and protein interaction domains of SHC adaptor in VEGF receptor 3 signaling," <u>Oncogene</u> 18:507-514 (1999)
	Fournier et al., "Interaction with the phosphotyrosine binding domain/phosphotyrosine interacting domain of SHC is required for the transforming activity of the FLT4/VEGFR3 receptor tyrosine kinase," <u>J. Biol. Chem.</u> 271:12956-12963 (1996)
	Galland, "The <i>FLT4</i> gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor," <u>Oncogene</u> 8:1233-1240 (1993)
	Hagedorn and Bikfalvi, "Target molecules for anti-angiogenic therapy: from basic research to clinical trials," <u>Crit. Rev. Oncol. Hematol.</u> 34:89-110 (2000)
	Hennequin et al., "Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors," <u>J. Med. Chem.</u> 42:5369-5389 (1999)
	Joukov et al., "Vascular endothelial growth factors VEGF-B and VEGF-C," <u>J. Cell. Physiol.</u> 173:211-215 (1997)
	Junghans and Collin, "Limbal lymphangiogenesis after corneal injury: An autoradiographic study," <u>Curr. Eye Res.</u> 8:91-100 (1989)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-AR 4951	SERIAL NO. 10/081-126
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT: Gerald W. De Vries  FILING DATE: February 22, 2002	GROUP: 3731 MAY 15 2002

	Karkkainen and Petrova, "Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis," <u>Oncogene</u> 19:5598-5605 (2000)
	Kirkin et al., "Characterization of indolinones which preferentially inhibit VEGF-C- and VEGF-D-induced activation of VEGFR-3 rather than VEGFR-2," <u>Eur. J. Biochem.</u> 268:5530-5540 (2001)
	Kirsch et al., "Anti-angiogenic treatment strategies for malignant brain tumors," <u>J. Neuro-oncol.</u> 50:149-163 (2000)
	Klagsbrun and D'Amore, "Vascular endothelial growth factor and its receptors," <u>Cytokine &amp; Growth Factor Rev.</u> 7:259-270 (1996)
	Korpelainen and Alitalo, "Signaling angiogenesis and lymphangiogenesis," <u>Curr. Opin. Cell Biol.</u> 10:159-164 (1998)
	Kubo et al., "Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis," <u>Blood</u> 96:546-553 (2000)
	Li and Eriksson, "Novel VEGF family members: VEGF-B, VEGF-C and VEGF-D," <u>Inter. J. Biochem. Cell Biol.</u> 33:421-426 (2001)
	Liu et al., "Cytokine signaling through the novel tyrosine kinase RAFK in Kaposi's sarcoma cells," <u>J. Clin. Invest.</u> 99:1798-1804 (1997)
	Maeno et al., "Three decades of corneal transplantation: Indications and patient characteristics," <u>Cornea</u> 19:7-11 (2000)
	Makinen et al., "Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3," <u>Nature Medicine</u> 7:199-205 (2001)
	McCallum et al., "Analysis of corneal and conjunctival microenvironments using monoclonal antibodies," <u>Invest. Ophthalmol. Vis. Sci.</u> 34:1793-1803 (1993)
	Millauer et al., "Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant," <u>Nature</u> 367:576-579 (1994)
	Mimura et al., "Expression of Vascular Endothelial Growth Factor C and Vascular Endothelial Growth Factor Receptor 3 in Corneal Lymphangiogenesis," <u>Exp. Eye Res.</u> 72:71-78 (2001)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-AR 4951	SERIAL NO. 10/081,126
	APPLICANT: Gerald W. De Vries	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: February 22, 2002	GROUP: 3731

	Mohammadi et al., "Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain," <u>EMBO J.</u> 17:5896-5904 (1998)
	Naacke et al., "Outcome of corneal transplantation rejection," <u>Cornea</u> 20:350-353 (2001)
	Nieder Korn, "The immunology of corneal transplantation," <u>Dev. Ophthalmol.</u> 30:129-140 (1999)
	Olofsson et al., "Current biology of VEGF-B and VEGF-C," <u>Curr. Opin. Biotech.</u> 10:528-535 (1999)
	Paavonen et al., "Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing," <u>Amer. J. Pathology</u> 156:1499-1504 (2000)
	Pajusola et al., "Two human FLT4 receptor tyrosine kinase isoforms with distinct carboxy terminal tails are produced by alternative processing of primary transcripts," <u>Oncogene</u> 8:2931-2937 (1993)
	Pajusola et al., "FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines," <u>Cancer Research</u> 52:5738-5743 (1992)
	Pajusola et al., "Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors," <u>Oncogene</u> 9:3545-3555 (1994)
	Petrova et al., "Signaling via vascular endothelial growth factor receptors," <u>Exper. Cell Res.</u> 253:117-130 (1999)
	Stacker and Achen, "The vascular endothelial growth factor family: signalling for vascular development," <u>Growth Factors</u> 17:1-11 (1999)
	Taipale et al., "Vascular endothelial growth factor receptor-3," <u>Curr. Top. Microbiol. Immunol.</u> 237:85-96 (1999)
	Tong et al., "A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket," <u>Nature Struct. Biol.</u> 4:311-316 (1997)
	Treseler, "The expression of HLA antigens by cells in the human cornea," <u>Am. J. Ophthalmol.</u> 98:763-772 (1984)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449 US Department of Commerce Patent and Trademark Office	APPY DOCKET NO: P-AR 4951	SERIAL NO. 10/081 126
	APPLICANT: Gerald W. De Vries	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: February 22, 2002	GROUP: 3731

		Veikkola et al., "Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice," <u>EMBO J.</u> 20:1223-1231 (2001)
		Waldock and Cook, "Corneal transplantation: How successful are we?," <u>Br. J. Ophthalmol.</u> 84:813-815 (2000)
		Wang et al., "Signal transduction in human hematopoietic cells by vascular endothelial growth factor related protein, a novel ligand for the FLT4 receptor," <u>Blood</u> 90:3507-3515 (1997)
		Wedge et al., "ZD4190: An Orally Active Inhibitor of Vascular Endothelial Growth Factor Signaling with Broad-Spectrum Antitumor Efficacy," <u>Cancer Research</u> 60:970-975 (2000)
		Wilson et al., "The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase," <u>Chem. &amp; Biol.</u> 4:423-431 (1997)
		Zachary and Gliki, "Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family," <u>Cardiovascular Res.</u> 49:568-581 (2001)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.